Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This am's exchange with Dr. Seymour.
Dr. Seymour. As NNVC close in on shipping Ebola cide to the USA.... I wonder if you could answer a few simple question for me and the many small retail investors whom I have convinced to invest the work you and Dr. Diwan have done? I believe from all I have learned over the years that the cides will work, and many more will be made. The oral version will be incredible. As I was showering and getting ready to brush my teeth a thought can to mind. What if those breath strips had a minute amount of a cide in them. Every day your system could have a little boost and help clear those nasty viruses, yea, a little far off, but oh the revenue stream.
Questions.
How many cides are "multiple" to be tested?
What volume of each cide will be shipped? (this because the 200g seemed to be a new number and 1g was an old one).. I know that you will ship enough but this will demonstrate that NNVC has the know how to produce the cides in the future on short notice.
TIA, Another_Voice_2 boB
EUGENE SEYMOUR
10:31 AM (4 hours ago)
to me
We usually produce 8 and ship them off for testing
Because of the urgency of the situation, we'll probably at least double that number or even make more
Enough for small animals and cell culture. As soon as we see what works best in small animals, we'll start making enough for non-human primates
Your cides idea is interesting. The possibilities are endless
Don't get hung up on 200 grams
We made what they needed to start
The Shelton plant will become the larger-scale producer
Eugene Seymour, MD MPH
Chief Executive Officer
NanoViricides, Inc
310-486-5677
A New York Stock Exchange Company
speeded up testing.
http://www.foxnews.com/health/2014/11/06/health-officials-unveil-plan-to-test-multiple-ebola-drugs-at-once/?intcmp=latestnews
November 5, 2014: This undated handout photo issued by Save the Children UK shows equipment still wrapped in plastic inside what will be the red zone of the Kerry Town Ebola Treatment Centre in Sierra Leone. (AP Photo, Louis Leeson/Save the Children UK)
NEW ORLEANS – The quest for an Ebola treatment is picking up speed. Federal officials have unveiled a plan to test multiple drugs at once, in an umbrella study with a single comparison group to give fast answers on what works.
"This is novel for us" and is an approach pioneered by cancer researchers, said Dr. Luciana Borio, head of the U.S. Food and Drug Administration's Ebola response. "We need to learn what helps and what hurts" and speed treatments to patients, she said.
She outlined the plan Wednesday at an American Society of Tropical Medicine and Hygiene conference in New Orleans. Thousands of scientists have crowded into day and late-night sessions on Ebola, which has killed 5,000 West Africans this year.
There is no treatment for Ebola, but several experimental ones such as ZMapp have been tried on a few patients, and scientists are eyeing some others that were developed for different conditions but may also fight Ebola.
"There's this tremendous urge to want to give people these experimental therapies" but it's crucial to make sure they don't do harm, said the FDA's Dr. Edward Cox.
Everyone in the umbrella study would get supportive care, such as intravenous fluids, then be assigned to receive one of several drugs or be in a comparison group. That's needed because without one, there's no way to know if any problems or deaths are from the drug or the disease, Cox said.
Instead of waiting until a certain number of patients are treated to look at results, as is usually done, researchers will monitor results as they come in, pairing each person on a drug with someone from the comparison group to see if a pattern can be detected.
The National Institutes of Health developed this "learn as you go" plan "to allow a winner to be declared very early," Cox said.
He said the FDA could not name the drugs being considered, but said a meeting next week with various companies should crystallize the plans.
Ten potential vaccines have been developed, and two should enter mid- to late-stage testing in December or January, Dr. Cathy Roth of the World Health Organization told the conference via Skype from Geneva. GlaxoSmithKline's is one of them, and it's too soon to say when it could be ready for wide use or what it would cost, said the company's Dr. W. Ripley Ballou.
Poor countries "can't be expected to pay for it," so groups that have given aid in the past likely will be asked to do that, he said.
At least 30 scientists were barred from the conference because Louisiana state officials told attendees to stay away if they had traveled to certain West African countries or had contact with an Ebola patient in the last 21 days, Ebola's maximum incubation period. One was Dr. Amanda Tiffany of Doctors Without Borders, who was to have given a talk on how to limit the spread of Ebola, based on her work on some of the very first cases in Guinea.
"The stigma American and other colleagues are now facing is great," she said in a statement read by a colleague. "We need information disseminated through the media based on science and medicine and not on fear."
Dr. Daniel Bausch, a Tulane University doctor who has worked on the outbreak and advised the government on policy, said travel bans and quarantines were hurting the Ebola response.
The phrase "abundance of caution" is code for doing something based on fear rather than science, he said. "I don't think it calms people's fears, I think it enhances people's fears."
Ebola is setting back even the crude health care available in West Africa. In Sierra Leone, there now are no doctors willing to do Caesarean sections on pregnant women — whether they are known to have Ebola or not — because of the fear of exposure to so much blood, said Dr. Lina Moses, another Tulane researcher who works in that country.
"Maternal health is a serious issue right now," she said. "We're expecting maternal mortality to skyrocket."
This isbig and yes should be read and understood! It seems above my pay grade, but I try. The message is that the Doc. knows what works and he makes it happen.
From Dr. Diwan, President NNVC and inventor of the underlying newly patented technology and other NNVC licensed patent applications:
Email, Thursday, May 10, 2012
The critical and important difference from these and many other technologies out there and nanoviricides® is that nanoviricides are not just polymer-based technologies.
Getting a polymer to bind to a specific site on a virus or a cell is not difficult. It can be accomplished with many polymers. However, most such polymers allow a ligand to be attached only at one or both ends of the polymer chain, resulting in a relatively low ligand density. In contrast, the patent describes novel polymers in which we can attach ligands at every repeat unit. This is a major innovation and has not been accomplished before. Binding to a polymer bearing ligands vs the cell surface receptors is the competition that the antiviral agent must win. The balance is strongly in favor of nanoviricides(r) due to the high ligand density we can theoretically accomplish.
It is not enough to bind to the virus. Such binding would create what may be termed a "precipitate" that would lead to an immune precipitate if the complement system is properly functioning, and then could get cleared by the immune system if the immune system is properly functioning at full capacity. We know from Virology that viruses are intelligent nanomachines and that they succeed in creating a severe infection in a human host only if they succeed in fighting out the host immune system. Most viruses derail the immune system in some way, and there are many different points where they derail it.
Most approaches being tried currently are based on rigid polymers. Examples- dendrimers, polylactate/polybutyrate and related polymers. The drugs based on these are essentially rigid particles. So the liganded polymer nanoparticle of such could stops at binding to the virus. It may bind to the more than one virus particles, itself appearing like a marble in the middle. However, their surface of interaction with an individual virus particle is small; it is only a tangential interaction.
The second and even more important key invention in our polymers is that they do not form fixed, rigid particles. They are "metastable" materials. What this means is that put a nanoviricide in water or aqueous phase (as in bodily fluids) and it would appear with ligands displayed outwards and the lipid chains hidden inside. If you put it in a lipidic environment (fatty/oily environment or organic solvent), it inverts itself inside out, and throws its lipid feet outside and pulls its water-loving parts inside. This is the key feature that allows for a strong interaction with a lipid surface such as virus. Upon binding to the virus, we believe that this metastability property enables the polymeric micelle to spread itself along the virus surface, becoming so thin that the lipid part of the polymer contacts the lipid coat on the virus. Then a well-known switching process called "lipid-lipd fusion" can take place. Many viruses are susceptible to such attack and would fall apart completely [typically, these are viruses that do not require excessive acidification before dismantling themselves in the natural course of infection].
A third feature disclosed in a later international patent application is that our polymeric micelle materials intended as antivirals provide acidic microenvironment, similar to that of endosomes in the cells wherein viruses dismantle themselves. This is why susceptible viruses such as MCMV, Influenza and HIV possibly fall apart on attack by a nanoviricide.
A fourth feature of nanoviricides technologies is that we DO NOT USE native substances, such as peptides or protein fragments derived from natural ligands. We believe that human system has those natural ligands because they are needed for some communication within the human system. We want to minimize interference to the host. Therefore, we develop chemical mimics of the conserved portion of the human receptor that binds to the virus attachment protein(s). We have also used Fab fragments and antibodies as ligands. The small chemical mimics that we develop have had the advantage of being small and thus allowing loading of a large number of ligands per unit mass of the drug.
In addition, the small chemical ligands we design and develop are much cheaper to produce than the antibodies, ligands, and peptides such as RANTES-petide fragment that others have employed.
In a mathematical sense, using an antibody or Fab fragment or a natural ligand peptide as a binding ligand is a zeroeth level approximation to the problem. To improve upon it, we design the kind of small chemicals ligands which could be considered a third or fourth generation ahead of using antibodies or peptide fragments.
I am not trying to attack other technologies brought up by others. We are aware of many more approaches. However, the level of effectiveness we have achieved in preclinical animal studies is astounding compared to the level of success reported for these other technologies.
We can let the results speak for themselves.
There are two antiviral nano-scale approaches advancing in commercialization ahead of NanoViricides, Inc.
One is Star Pharma which employs a dendrimer-based polymer with naphthalene-disulfonate or Sudan-Black mimic-based ligands for microbicide-like placement in (a) vaginal gels and (b) condom gels so that the gel can act as an antiviral, more specifically, as anti-HIV. I submit that if these polymers were suitable for a direct anti-HIV drug intervention, this public company would have trumpeted and developed them for that application. They are in Phase III as microbicide in vaginal gel application. Similar negatively charged polymers have previously failed in Ph 3 clinical studies as microbicides. We hope Star Pharma fares better. However, it does not make an anti-HIV drug.
Another is NanoBio, which is developing oily substances modified to bear certain types of ligands for specific attack. This technology helped them develop an anti-herpes labialis cream. It has a similar mechanism of action, but each molecule bears only one ligand to bind to the virus as far as we can assess (on the same basis as we can claim that a nanoviricide has a large number of evenly spaced ligands). The approach is similar to or equivalent to liposomes. The limitations of this approach have become evident from a large number of drugs that have been developed and even commercialized based on this approach (and a far larger number of drugs that have been developed but that have failed to reach commercialization). In fact our original technology, patent issued in 2000, was developed to overcome several of the limitations of liposome technologies. And those old technology materials have been shown to be superior to liposomes.
With the new technology, we have made our own 2000-era and earlier technologies obsolete, we believe.
Most scientists and researchers have focused on a single issue and developed solutions relevant to that single issue. We were the first since 1991 to develop a Systems Engineering approach to development of medicines. A sub-part of the Systems Engineering for Medicines is called Systems Biology, which came into vogue circa 2005. We take into consideration not only the Systems Biology, but also the physicochemical and pharmaco-chemical aspects, aspects related to engineering and engineering design for scale-up to cGMP production, aspects related to transportation and delivery of the drug through the supply chain to the pharmacist, then to the patient, and then into the patient's bodily system. Many drugs fail as they advance in the discovery and development process because they fail to meet some of these criteria. We set out these criteria before synthesizing even one chemical. We can proudly say that every substance that we have made has shown clinical effectiveness in animal models, and most have shown effectiveness far superior to the standard-of-care. Our materials have also been safe to date in a large number of varied types of animal studies. That is the power of our Systems Engineering approach. We were uniquely qualified to employ this approach because I in person have training in Chemical Engineering, Chemistry, Biochemistry, Microbiology, Infectious Diseases, Biopolymers, Hematology, Blood Compatibility, as well as Virology. I do not claim to be an expert in any one of these disciplines; I and our team rely on experts for every step that we take. But there is clearly a multidisciplinary fusion that has been active in out team for as long as we have been working.
Sincerely,
Anil R. Diwan, Ph.D.
President
The oral pill will make a huge difference in the way the public looks at viruses. I can see a pharmacy with a wall full of bottles with different viruses names on them. Temperature is not a factor as the cides are stable at ambient temperatures.
KARNAC says ..... buy NNVC
I am all in so all I can do is encourage you to put more in this sound investment. I have done this for my grand kids portfolio. College will be paid for, IMHO
Delay Post. Thanks for reposting. This will give MHO more exposure.
Delays are a thing of the past. The cides have been shipped to the lab (BASi) for tox testing. Dr. S has stated that the 200g are sufficient to start the testing and that quantities for all the next steps will be made in time for CONTINOUS testing.
NNVC is a BIOTECH company using chemistry to interact with organic organisms. Making the next batches of Flucide is similar to a chemistry experiment. And it is predictable when done EXACTLY as Dr. D. has work out. Remember FLUCIDE will be the money horse to drive the earning per share.
Ebola is the bell cow. It has the media and health organization jacked up. Flu will kill a multiple of people more than Ebola. But it is sexier and has the headlines. The money will be grants or awards, not from sales of the cide. But, it looks like big numbers are on the table. Our smart Dr. D has hedged his bet and produced multiple candidates and will let the Army pick the best and go from there. Making enough for this subset of virus problems will be handled as results demand. NNVC has now a new lab that can be occupied and used to produced either choice.
The EB2 cide will be game changer as the world has it's eyes on Ebola and will validate our backbone.
IMHO
This is a great post! It shows us how much room we have for PPS appreciation.
The call for $500.00 per share is in play soon. (see my next post)
Yes, and in Bio tech way longer. As a product NNVC cides have the GREATEST potential to change the course of history! I am all in on the rocket ship that has just (shipped material to be tox tested) been launched.
The answer to your question is NO.
NNVC has had no ADVERSE events that would generate a PR.
Hi AZnavour! Do you know one of my mantras?
In biotech no news is good news
Each day NNVC marches toward to goal line. If any adverse event should occur it would need to be PR immediately! I can site many case to back this up. If you were to check Geron for example you could see what I mean. In the mean time daily progress continues. AS to Ebola and NNVC they are proceeding at FLANK speed. Everyone in the company is laser focused on getting the cide candidates to Ft. Detrick's labs.
opied this
The Ebola crisis reveals how useless the FDA is.
If you're worried about the Ebola crisis, don't worry. Government bureaucrats are on the case!
Not exactly reassuring given that the bureaucratic incompetence of the World Health Organization is what allowed the breakout to get so big to begin with. And the U.S. government's own efforts so far are far from reassuring.
But don't worry: The FDA is on it. The organization recently fast-tracked two types of Ebola tests for use. And other experimental treatments have been used with governmental blessing, with encouraging results. This begs an admittedly simplistic pair of questions: If these treatments are safe, why weren't they already approved? If they are not safe, why approve them now?
Many people have criticized the FDA over the years for its uselessness. Tort laws and regulations and fear of scandal are by themselves very useful at giving drug and medical companies a very strong incentive to market only safe drugs and remedies. (Not to mention that general principle of a competitive marketplace, which is that in general and overall, you will do better with a good product than with a shoddy product.)
There is simply no reason for the FDA to exist, other than some obscurantist fear of drugs and supposedly evil drug companies.
But the FDA is not just useless. It is actively harmful. The biotech industry has a phrase for this government obstruction: Eroom's Law. "Eroom" is "Moore" backwards. The reference is to the well-known Moore's Law, which dictates that computer chips get better and cheaper over time at an astronomic rate.
Just like Moore's Law presides over our astonishingly vital information technology, its opposite, Eroom's Law, lords over the biotech industry and holds it back. And Eroom's Law is largely based on organizations like the FDA, which demand ever-more rigorous standards to bring drugs to market.
TRENTON, N.J. -- The New Jersey Department of Health says a woman who arrived at Newark Liberty International Airport from West Africa and was the first traveler to be quarantined under new Ebola protocols has developed a fever.
The woman, a health care worker who had been treating Ebola patients in Sierra Leone, is in isolation and being evaluated at University Hospital in Newark, according to CBS New York.
The Department of Health could not say what flight the woman was on or whether other passengers were involved.
Play Video
Nurses who treated Duncan tell their story
Dr. Howard Zucker, acting New York state health commissioner, said any medical personnel who have treated Ebola patients in Sierra Leone,
last shares @ 3.95 so a big up day!
please sticky note changes post
Sir, your post cost me soe sleep. Google to the rescue.
1 liter of water has mass about 1000 grams/liter. Water has molecular weight about 18 grams/mole (2 hydrogens = 2, 1 oxygen = 16). So that is 1000/18 = 55 moles/liter. A mole is 6 x 10 to the 23 power (6.023x10^23) molecules.
Molecules in Cup of Water - NEWTON Ask A Scientist
www.newton.dep.anl.gov/askasci/chem03/chem03149.htm
75 trillion 75,000,000,000,000 is a twelve power. so I bet the number is in the ball park.
If we all divided a CC and started to count we would not get there in our life time.
Reply to both earlier post simplied by Dr.Seymour.
eugeneseymourmd@mac.com
4:58 PM (24 minutes ago)
to me
Each 5cc dose contains 75 trillion nanoviricides
Many more than the number of virus particles
The drug lasts at least 30 days in the circulation so its killer effect is prolonged
We don’t want to give multiple doses
I can’t tell you more about the testing protocol until it’s finalized
Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
eugene@nanoviricides.com
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange
Nice close last 5 minutes good vol and price traded up to only down .01 for the day!
BigK, The current flu vaccines do have side effects and are not 100% effective. To think that a vaccine will work against 400 mutations with one shot would be unimaginable.
As to making one westerner sick, we would need to define that.
The time frame to come up with a safe effective Enola vaccine would be very long.
EB2 or EB3 or ?? doesn't take as long as they should be agnostic to the cells of the body!
Let's see it my line of reasoning is valid. Since we don't know if, as in my earlier post that multiple doses of EB2 will be tried, what to expect of the test vs the EB1 test.
Lets say the 100% dose killed in 5 days.
The EB1 animals lived 6.5 days(?), a 30% extension of life.
The multiple EB2 candidates find one or more with a 7.5 day extension.
Would this be considered success?
Would you suggest changing the protocol to include multiple dose until remission or death occurs(if this isn't a part of the testing now)?
JG36 your confusing, deliberately, the public vs private.
Dr..65 your 100% right on
Why hasn't this been discussed before. Given a 100% dose of the virus killed 100% of the animals. Some just lived longer because NNVC Ebolacide mechanism of action is unique.
The cide is an active particle! It can not reproduce itself. So on a physical basis if an infusion of ~3,000,000 particles (just a guess) kills 3,000,000 virus cells the viral load is reduced. The viruses that are still active can and do reproduce and can increase their activity until the animal dies. It just takes longer. I.E. extended life because it was working.
The protocol should have been changed. Multiple doses were need to root out all the virus particles. Remember it is the bodies' immune system job to produce the correct antibody to cleanup any virus particle remaining in the system. NNVC is only a very powerful aid to making the animal well.
I reposted many of the post on fb nano club incase they get deleted. Thanks for such strong support.
But maybe one of them or more will be the magic bullet. As to the hydration that would have been taken into consideration.
The information about the fever being present inanely 80% of infected people is very discoursing to me.
If the US allows 100 people who have Ebola to enter the us for treatment, that means these 100 have a fever.
It will also mean that we have a lax policy toward prevention of Ebola entering the us. So many without a fever will enter and start to spread the disease.
expecting it...not so, the good Dr. Diwan's creditability is on the line. NNVC showed an increase in life the last time, not a 100% cure. But enough that it had some efficacy. With that knowledge and the new information about how Ebola evades detection Dr. Diwan has designed a new ligand to increase the probability of success. The fact that he has made multiple candidates and even eluded to a EB3 tells us that this is a very tricky virus.
Related to this epidemic.
Lewiston, Idaho Veterinarian's Letter to the Editor
Re: Ebola
The present Ebola crisis in the world is frightening. I have submitted the following letter to the editor of the Lewiston Morning Tribune:
Editor, Lewiston Morning Tribune:
If I wish to import a horse into the United States from Liberia or any African country other than Morocco, the horse needs to undergo a 60-day quarantine period at a USDA approved quarantine facility prior to mingling with the general population of horses in this country. Africa has a disease called African Horse Sickness that does not exist in the US; this is the way we have kept it out of this country. African Horse Sickness does not cause disease in people, only horses; our government has determined that it would be devastating to the U.S. horse industry if it were to come here.
The United States (and virtually all other countries) require myriad tests and often quarantine prior to bringing in a foreign animal.
I can’t legally cross state lines in the United States with a horse or cow without a health certificate signed by a USDA accredited veterinarian stating that the animal has been inspected and found free of infectious disease. In most cases blood tests are also required. In fact I can’t legally cross the Snake River and ride my horse in Idaho without a health certificate and a negative blood test for Equine Infectious Anemia.
I’m not complaining; the United States of America, the States of Idaho and Washington as well as the other 48 states take the health of our livestock very seriously, and we have a very good record at keeping foreign animal diseases out of our country. I am happy to do my part to maintain biosecurity in our animal population.
If I am a resident of Liberia incubating Ebola, however, to enter the United States, all I need to do is present a valid visa, and lie when asked if I have been exposed to Ebola. Within hours (no quarantine required) I can be walking the streets of any city in the United States.
I feel very fortunate to live in a country that values our animals so highly. Even above all human beings…!
David A. Rustebakke, DVM
Again Changes you are so good a writing and blogging the information. I want to buy you 2 drinks (a safelimit I hope) in HI! Thanks for your work!
Why I am all in and a repeat of how to test the cides.
Testing EB2
Facts
1. NNVC’s cides are agnostic.
2. 6,000 animals tested and no toxicity found.
3. Ebolacide1 had some efficacy, just not enough.
4. More information about the virus is now known.
5. The Ebola outbreak is growing and killing people.
6. Flucide is off to BASi.
7. Read Big K list of other tests in progress.
NNVC is developing and producing multiple candidates for dismantling the virus particles. These candidates will be tested in a BSL-4 lab. The protocol that will be used has not been disseminated. As a layman and thinker I have a suggestion as how to test the efficacy of the new EB2 candidates.
1. Drawer blood from a corps to use as a sample.
2. Drawer blood from a brother or sister who is a blood type match.
3. Fly both samples to a BSL-4 lab.
4. Check both samples to ensure one is clean and the infected sample shows the virus.
5. Use as many tubes of infected samples as you have candidates.
6. Also use a clean sample with a cide for comparison. One for each candidate.
7. Agitate them to allow the cide candidate cides to mate with the virus.
8. Check each sample and compare to the original.
9. Report the results!!
Now if one works well make a batch and try it in infected patients with informed consent.
From a person who wants the outbreak to stop!
p 2 more cents in the ah, nothing big, but better than down.
Gee, your absolutely correct for a change!
19,526 shares at 3.95 is a strong BOC for NNVC. Lots more legs before the year is over. Too many irons in the fire with NNVC hitting on all cylinders.
Your probably right that there will be lots of legs when it starts to roll, but the number of shares at low prices is what you want.
I don't trade, I am "all in". The action today looks as if the MM are buying for a strong BOC. IMHO.
Sorry to see you go. next stop Is 5.25, then ....
Federal government and non-Federal partners to optimize their resources, share technical expertise in a protected environment, share intellectual property emerging from the effort, and speed the commercialization of federally developed technology.
How I readthe CRADA as regard to NNVC asa business. A CRADA is an excellent technology transfer tool. It can:
* Provide incentives that help speed the commercialization of federally-developed technology.
NNVC. This is good for us.
* Protect any proprietary information brought to the CRADA effort by the partner.
NNVC. This is good for us.
* Allow all parties to the CRADA to keep research results emerging from the CRADA confidential and free from disclosure through the Freedom of Information Act for up to 5 years.
NNVC. This is good for us.
* Allow the government and the partner to share patents and patent licenses.
NNVC. This is good for us. This allows NNVC to not share their IP with the government!
* Permit one partner to retain exclusive rights to a patent or patent license.
NNVC. This is good for us.
All in my humble opinion.
Yes, and then it would be a vaccine and not a crure
Good point Big K. Since the Army can use different rules, and they are sending troops to Africa who will be in HARMS WAY Ebola cide might be used to cure a sick soldier.
Big K, The use of Ebola cide should not depend on a raging virus. Even if it slows to a crawl Ebola cide should be used to keep people alive. I do not expect the 70% fatal rate to change. And if there is only one person with the virus the epidemic can restart! Since no other CURE is or will be available the NNVC cide should be allowed with informed consent ASAP!
imho WITH no alternative the primate step should be skip or pushed to the head of the testing cycle NOW! Again IMHO
UP to 3.57 ah +.17 200 shares